HPLC-ELSD法测定银杏内酯B脂微球中银杏内酯B的含量
|
摘要
建立了银杏内酯B脂微球中银杏内酯B的含量测定方法。采用HPLC法,色谱柱为C18柱(250mm×4.6mm,5μm),流动相为甲醇-四氢呋喃-水(25∶10∶65),流速为1.0mL·min-1,柱温为30℃,蒸发光散射检测器,载气压力为4.0bar,漂移管温度40℃。结果银杏内酯B在80.91～269.70μg·m L-1时,线性关系良好(r=0.9998),平均加样回收率为100.25%,RSD为1.44%。该法准确,重现性好,可用于银杏内酯B脂微球中银杏内酯B的含量测定。
An HPLC method for determination of ginkgolide B in ginkgolide B lipid microsphere was established. The Chromatographic column was C18 column(250×4.6 mm, 5μm), the mobile phase was methanol-tetrahydrofuran-water(25∶10∶65), the flow rate was 1 mL·min-1, the column temperature was 30℃, the detector was ELSD,the carrier gas pressure was 4.0 bar and the drift tube temperature was set at 40℃. Ginkgolide B had a good linear relation in the range of 80.91-269.70μg·mL-1(r=0.9998). The average recovery was 100.25% and the RSD was1.44%. The method is accurate, reproducible and applicable for determination of ginkgolide B in ginkgolide B lipid microsphere.
An HPLC method for determination of ginkgolide B in ginkgolide B lipid microsphere was established. The Chromatographic column was C18 column(250×4.6 mm, 5μm), the mobile phase was methanol-tetrahydrofuran-water(25∶10∶65), the flow rate was 1 mL·min-1, the column temperature was 30℃, the detector was ELSD,the carrier gas pressure was 4.0 bar and the drift tube temperature was set at 40℃. Ginkgolide B had a good linear relation in the range of 80.91-269.70μg·mL-1(r=0.9998). The average recovery was 100.25% and the RSD was1.44%. The method is accurate, reproducible and applicable for determination of ginkgolide B in ginkgolide B lipid microsphere.
引文
[1]张学非,曹泽彧,许治良,等.银杏内酯治疗脑缺血作用机制的研究进展[J].中草药,2016,47(16):2943-2948.
[2]蒋文潇,王保和.银杏内酯对缺血性脑血管疾病的药理研究进展[J].辽宁中医杂志,2015,42(2):441-444.
[3]王旋,张慧灵,顾振纶,等.银杏内酯药理作用的研究进展[J].中草药,2005,36(11):1741-1744.
[4]张观涛,焦豪妍,索其良.银杏内酯B注射液大鼠药代动力学研究[J].中药材, 2012, 35(3):430-433.
[5]蔡晓蕾,陈卫东.银杏内酯B剂型研究进展[J].安徽中医学院学报,2013,32(1):86-90.
[6]蒋永红,王佩维,张高勇,等.表面活性剂增溶银杏制剂[J].日用化学工业,2002,32(2):8-10.
[7] Liu ZZ,Feng YY,Zhang LL,et al. Pharmacokinetics and tissue distribution of larotaxel in rats:comparison of larotaxel-loaded microsphere with larotaxel-solution[J].Cancer Chemother Pharmacol,2013,71(5):1131-1139.
[8] Mc Clements DJ. Advances in fabrication of emulsions with enhanced functionality using structural design principles[J]. Curr Opin Colloid Interf Sci.,2012,17(5):235-245.
[9] Akkar A,Muller RH. Intravenous itraconazole emulsions produced by Sol Emuls technology[J].Eur. J. Pharm Biopharm,2003,56(1):29-36.
[10] Müller RH,Schmidt S,Buttle I,et al. Sol Emuls-novel technology for the formulation of i.v.emulsions with poorly soluble drugs[J].Int. J. Pharm,2004,269(2):293-302.
[11] Yue PF,Li FQ,Liao MX,et al. Process optimization,characterization,and release study in vitro of an intravenous puerarin lipid micropheres loaded with the phospholipid complex[J]. J. Dispers Sci. Technol,2011,32(1):1-10.
[12] Yue PF,Zheng Q,Wu B,et al. Application of plackett-burman design and box-behnken design to achieve process optimization for geniposide submicron emulsion[J]. J. Dispers Sci. Technol,2012,33(2):213-222.
[13] Ma YQ,Li G,Xu JH,et al. Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid[J]. Pharm Dev. Technol,2014,19(3):363-372.
[14]孙俊,陈志鹏,蔡宝昌.银杏叶提取物磷脂复合物的制备[J].中华中医药学刊, 2009,27(12):2671-2673.
[15]高蓓.HPLC-ELSD法测定银杏滴丸中银杏内酯A、B、C和白果内酯[J].中草药,2010, 41(2):236-238.
[2]蒋文潇,王保和.银杏内酯对缺血性脑血管疾病的药理研究进展[J].辽宁中医杂志,2015,42(2):441-444.
[3]王旋,张慧灵,顾振纶,等.银杏内酯药理作用的研究进展[J].中草药,2005,36(11):1741-1744.
[4]张观涛,焦豪妍,索其良.银杏内酯B注射液大鼠药代动力学研究[J].中药材, 2012, 35(3):430-433.
[5]蔡晓蕾,陈卫东.银杏内酯B剂型研究进展[J].安徽中医学院学报,2013,32(1):86-90.
[6]蒋永红,王佩维,张高勇,等.表面活性剂增溶银杏制剂[J].日用化学工业,2002,32(2):8-10.
[7] Liu ZZ,Feng YY,Zhang LL,et al. Pharmacokinetics and tissue distribution of larotaxel in rats:comparison of larotaxel-loaded microsphere with larotaxel-solution[J].Cancer Chemother Pharmacol,2013,71(5):1131-1139.
[8] Mc Clements DJ. Advances in fabrication of emulsions with enhanced functionality using structural design principles[J]. Curr Opin Colloid Interf Sci.,2012,17(5):235-245.
[9] Akkar A,Muller RH. Intravenous itraconazole emulsions produced by Sol Emuls technology[J].Eur. J. Pharm Biopharm,2003,56(1):29-36.
[10] Müller RH,Schmidt S,Buttle I,et al. Sol Emuls-novel technology for the formulation of i.v.emulsions with poorly soluble drugs[J].Int. J. Pharm,2004,269(2):293-302.
[11] Yue PF,Li FQ,Liao MX,et al. Process optimization,characterization,and release study in vitro of an intravenous puerarin lipid micropheres loaded with the phospholipid complex[J]. J. Dispers Sci. Technol,2011,32(1):1-10.
[12] Yue PF,Zheng Q,Wu B,et al. Application of plackett-burman design and box-behnken design to achieve process optimization for geniposide submicron emulsion[J]. J. Dispers Sci. Technol,2012,33(2):213-222.
[13] Ma YQ,Li G,Xu JH,et al. Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid[J]. Pharm Dev. Technol,2014,19(3):363-372.
[14]孙俊,陈志鹏,蔡宝昌.银杏叶提取物磷脂复合物的制备[J].中华中医药学刊, 2009,27(12):2671-2673.
[15]高蓓.HPLC-ELSD法测定银杏滴丸中银杏内酯A、B、C和白果内酯[J].中草药,2010, 41(2):236-238.